Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
AbCellera Biologics Inc. ABCL
$5.72
-$0.02 (-0.35%)
На 18:03, 12 мая 2023
+385.14%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1618233840.00000000
-
week52high
14.97
-
week52low
5.42
-
Revenue
485424000
-
P/E TTM
11
-
Beta
-0.11692600
-
EPS
0.49000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 20:00
Описание компании
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Credit Suisse | Outperform | Outperform | 10 авг 2022 г. |
| Piper Sandler | Overweight | Overweight | 26 июл 2022 г. |
| SVB Leerink | Outperform | Outperform | 11 мая 2022 г. |
| Piper Sandler | Overweight | Overweight | 11 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 25 февр 2022 г. |
| Truist Securities | Buy | 16 ноя 2022 г. | |
| SVB Leerink | Outperform | Outperform | 09 ноя 2022 г. |
| SVB Leerink | Outperform | Outperform | 06 янв 2023 г. |
| Goldman Sachs | Buy | 15 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Booth Andrew | D | 5820481 | 50000 | 20 дек 2022 г. |
| Booth Andrew | D | 138500 | 50000 | 20 дек 2022 г. |
| Booth Andrew | A | 188500 | 50000 | 20 дек 2022 г. |
| Thermopylae Holdings Ltd. | A | 55859493 | 85102 | 16 дек 2022 г. |
| Lo Andrew | A | 138556 | 47231 | 01 дек 2022 г. |
| Montalbano John S. | A | 627045 | 47231 | 01 дек 2022 г. |
| Hayden Michael R | A | 497045 | 47231 | 01 дек 2022 г. |
| Lecault Veronique | A | 3392689 | 462535 | 01 дек 2022 г. |
| Stimart Tryn | A | 2658381 | 346901 | 01 дек 2022 г. |
| Booth Andrew | A | 5870481 | 485661 | 01 дек 2022 г. |
Новостная лента
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
InvestorPlace
02 февр 2023 г. в 14:19
You don't have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edge of medical science.
AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023
Business Wire
01 февр 2023 г. в 16:05
VANCOUVER, British Columbia--( BUSINESS WIRE )--AbCellera (Nasdaq: ABCL) today announced that it will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023, at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time).
Is the Options Market Predicting a Spike in AbCellera (ABCL) Stock?
Zacks Investment Research
24 янв 2023 г. в 10:33
Investors need to pay close attention to AbCellera (ABCL) stock based on the movements in the options market lately.
AbCellera Biologics: My Updated Current Valuation Estimate
Seeking Alpha
05 янв 2023 г. в 02:57
In this article, I will provide my valuation model for AbCellera, building on an article I wrote over a year ago. In the last year, many of my inputs I previously used have changed, given the greater transparency of the company throughout 2022. Some for the better, some for the worse.
10 Potential 10x Return Stocks For The Next 10 Years
Seeking Alpha
04 янв 2023 г. в 11:04
While others flock to safety, should you do the opposite? Some of the best times to invest in highly speculative names are when no one wants them, as long as the reasons are macro and not company or industry specific.